X
UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit
https://pharmaphorum.com/views-and-analysis/uk-biotech-roundup/
CAR T
GSK takes option to develop T-cell therapy with Adaptimmune
September 8, 2017
Cellectis CAR-T trials on hold after patient death
September 5, 2017
Innovations in cancer drug research
September 4, 2017
Oxford BioMedica could get $100m following CAR-T approval
September 1, 2017UK biotech will supply key component of Novartis’ newly approved cancer cell therapy
Gilead swoops to buy Kite for $12billion
August 28, 2017Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
Real world data essential for CAR-T therapy success
August 14, 2017Innovators will need to quantify value to bring costly drugs to market.
Kite begins EU trial of CAR-T therapy
August 8, 2017First patient has received axi-cel in Amsterdam hospital.
